Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, P.O. Box 80203, Jeddah, Saudi Arabia.
Therapeutic and Protective Proteins Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications, New Borg EL-Arab, Alexandria, 21934, Egypt.
Protein J. 2019 Aug;38(4):479-496. doi: 10.1007/s10930-019-09828-5.
Current study aimed to analyze the synergistic killing of pathogenic Escherichia coli using camel lactoferrin from different Saudi camel clans and various antibiotics. Methods: using multiple microbiological and protein analysis techniques, the results were shown that the purified camel lactoferrins (cLfs) from different Saudi camel have strong antimicrobial potentials against two strains of E. coli. Although all cLfs were superior relative to human or bovine lactoferrins (hLf or bLf), there was no noticeable difference in the antimicrobial potentials of cLfs from different camel clans. The effects of antibiotics and cLfs were synergistic, indicating the superiority of using cLf-antibiotic combinations against E. coli growth. Since these combinations possessed distinguished synergy profiles, it is likely that they can be used to enhance the low efficacy of antibiotics, as well as to control the problems associated with bacterial resistance. Furthermore, these combinations can reduce the cost of cure of bacterial infections, especially in the developing countries. The analysis of the molecular mechanisms of lactoferrin action revealed that expression of several E. coli proteins was affected by the treatment with these antibacterial factors. Several proteins of different molecular weights interacting with cLf-biotin were found. Scanning and transmission electron microscopy analysis revealed the presence of noticeable morphological changes associated with the treatment of E. coli strains by antibiotic carbenicillin or cLf alone, and in combination. Camel lactoferrin has superior potential killing of E. coli over bovine and human lactoferrin, and this potential can be further synergistically enhanced of cLF is combined with antibiotics.
本研究旨在分析使用来自不同沙特骆驼族群的骆驼乳铁蛋白和各种抗生素协同杀死致病性大肠杆菌。方法:使用多种微生物学和蛋白质分析技术,结果表明,来自不同沙特骆驼的纯化骆驼乳铁蛋白(cLfs)对两种大肠杆菌菌株具有很强的抗菌潜力。尽管所有 cLfs 相对于人或牛乳铁蛋白(hLf 或 bLf)都具有优势,但不同骆驼族群的 cLfs 抗菌潜力没有明显差异。抗生素和 cLfs 的作用具有协同作用,表明使用 cLf-抗生素组合对抗大肠杆菌生长具有优越性。由于这些组合具有独特的协同作用谱,因此它们可能被用于增强抗生素的低疗效,以及控制与细菌耐药性相关的问题。此外,这些组合可以降低治疗细菌感染的成本,特别是在发展中国家。乳铁蛋白作用的分子机制分析表明,几种大肠杆菌蛋白的表达受到这些抗菌因子处理的影响。发现了与 cLf-生物素相互作用的几种不同分子量的蛋白质。扫描和透射电子显微镜分析显示,在单独用抗生素卡那霉素或 cLf 以及联合处理大肠杆菌菌株时,存在明显的形态变化。骆驼乳铁蛋白对大肠杆菌的杀伤潜力优于牛和人乳铁蛋白,并且这种潜力可以通过与抗生素联合使用进一步协同增强。